WuXi AppTec raises guidance while WuXi AppTec stock costs EUR 23.63

Published on 10/12/2026 at 10:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 revenue reached RMB 28.897 billion, up 38.93 percent year over year. WuXi AppTec stock costs EUR 23.63 on October 12, 2026.

Key points in brief

WuXi AppTec raised full-year 2026 revenue guidance to RMB 58.5-60.5 billion.
First-half 2026 revenue reached RMB 28.897 billion, up 38.93 percent year over year.
WuXi AppTec stock was EUR 23.63 at Lang & Schwarz on October 12, 2026 at 10:46 a.m. CEST.
The next earnings date is October 27, 2026.

WuXi AppTec, CNE100003F19, Illustration mit AI erstellt.

WuXi AppTec raised its full-year 2026 revenue guidance from RMB 51.3-53.0 billion to RMB 58.5-60.5 billion, while WuXi AppTec stock was at EUR 23.63 at Lang & Schwarz on October 12, 2026 at 10:46 a.m. CEST. Biosynergy Pharma reported the guidance change on September 24, 2026.

H1 revenue reaches RMB 28.897 billion

WuXi AppTec generated RMB 28.897 billion of revenue in the first half of 2026, an increase of 38.93 percent from the same period a year earlier. Net profit attributable to shareholders reached RMB 11.080 billion, up 29.43 percent year over year, while adjusted non-recurring net profit rose 89.39 percent to RMB 10.572 billion, according to Biosynergy Pharma.

The TIDES business, covering oligonucleotides and peptides, produced RMB 7.26 billion of first-half 2026 revenue, up 44.30 percent year over year. That growth exceeded the company's overall revenue increase and gives the CRDMO group a second operating engine beyond its established chemistry platform.

What does the guidance mean?

The revised revenue range implies a higher full-year target than the earlier RMB 51.3-53.0 billion range, while the capital expenditure target also rose from RMB 6.5-7.5 billion to RMB 7.5-8.5 billion. The figures point to a strategy that pairs demand growth with faster capacity expansion, including an accelerated Changzhou base, as described by Biosynergy Pharma.

Three dated operating signals

On June 30, 2026, the first-half report period ended with revenue of RMB 28.897 billion and TIDES revenue of RMB 7.26 billion. On July 16, 2026, Huachuang Securities initiated coverage with a Strong Buy rating and a RMB 179.78 target, as reported by Gawin. On October 7, 2026, WuXi AppTec received its third consecutive EcoVadis Gold medal, according to WuXi AppTec.

Next reporting date is October 27

The next earnings report is scheduled for October 27, 2026, according to Investing.com. That date will give investors the first reported reading after the higher revenue and capital expenditure targets were published.

Stock trades at EUR 23.63

WuXi AppTec stock was at EUR 23.63 at Lang & Schwarz on October 12, 2026 at 10:46 a.m. CEST. Its primary Hong Kong listing is ticker 2359 on the Hong Kong Stock Exchange.

The further course of trading is shown by the continuously updated real-time quote of WuXi AppTec stock.